Neurofilaments as a plasma biomarker for ICU-acquired weakness: an observational pilot study

Wieske, L; Witteveen, E; Petzold, A; Verhamme, C; Schultz, MJ; van Schaik, IN; Horn, J

Journal article

Neurofilaments as a plasma biomarker for ICU-acquired weakness: an observational pilot study

Abstract:: Abstract Introduction Early diagnosis of intensive care unit – acquired weakness (ICU-AW) using the current reference standard, that is, assessment of muscle strength, is often hampered due to impaired consciousness. Biological markers could solve this problem but have been scarcely investigated. We hypothesized that plasma levels of neurofilaments are elevated in ICU-AW and can diagnose ICU-AW before muscle strength assessment is possible. Methods For this prospective observational cohort study, neurofilament levels were measured using ELISA (NfH SMI35 antibody) in daily plasma samples (index test). When patients were awake and attentive, ICU-AW was diagnosed using the Medical Research Council scale (reference standard). Differences and discriminative power (using the area under the receiver operating characteristic curve; AUC) of highest and cumulative (calculated using the area under the neurofilament curve) neurofilament levels were investigated in relation to the moment of muscle strength assessment for each patient. Results Both the index test and reference standard were available for 77 ICU patients. A total of 18 patients (23%) fulfilled the clinical criteria for ICU-AW. Peak neurofilament levels were higher in patients with ICU-AW and had good discriminative power (AUC: 0.85; 95% CI: 0.72 to 0.97). However, neurofilament levels did not peak before muscle strength assessment was possible. Highest or cumulative neurofilament levels measured before muscle strength assessment could not diagnose ICU-AW (AUC 0.59; 95% CI 0.37 to 0.80 and AUC 0.57; 95% CI 0.32 to 0.81, respectively). Conclusions Plasma neurofilament levels are raised in ICU-AW and may serve as a biological marker for ICU-AW. However, our study suggests that an early diagnosis of ICU-AW, before muscle strength assessment, is not possible using neurofilament levels in plasma.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Wieske, L., Witteveen, E., Petzold, A., Verhamme, C., Schultz, M. J., van Schaik, I. N., & Horn, J. (2014). Neurofilaments as a plasma biomarker for ICU-acquired weakness: an observational pilot study. Critical Care, 18(1), R18–R18.

MLA Style

Wieske, L, et al. “Neurofilaments as a Plasma Biomarker for ICU-Acquired Weakness: an Observational Pilot Study.” Critical Care, vol. 18, no. 1, 2014, pp. R18–R18.

Chicago Style

Wieske, L, E Witteveen, A Petzold, et al. 2014. “Neurofilaments as a Plasma Biomarker for ICU-Acquired Weakness: an Observational Pilot Study.” Critical Care 18 (1): R18–R18.
Print